BLENREP

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Lithuania, Poland, UK.

Active ingredients

The drug BLENREP contains one active pharmaceutical ingredient (API):

1	Belantamab mafodotin UNII DB1041CXDG - BELANTAMAB MAFODOTIN
	Belantamab mafodotin is a humanised IgG1κ monoclonal antibody conjugated with a cytotoxic agent, maleimidocaproyl monomethyl auristatin F (mcMMAF). Belantamab mafodotin binds to cell surface BCMA and is rapidly internalised. Apoptosis induced by belantamab mafodotin is accompanied by markers of immunogenic cell death, which may contribute to an adaptive immune response to tumour cells.
	Read more about Belantamab mafodotin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
BLENREP Powder for solution for injection	MPI, US: SPL/PLR	FDA, National Drug Code (US)
BLENREP Powder for concentrate for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01FX15	Belantamab mafodotin	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FX Other monoclonal antibodies
Discover more medicines within L01FX15

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1826265
FI	Lääkealan turvallisuus- ja kehittämiskeskus	175482
FR	Base de données publique des médicaments	69857522
GB	Medicines & Healthcare Products Regulatory Agency	396098
HK	Department of Health Drug Office	67213
IL	מִשְׂרַד הַבְּרִיאוּת	9007
LT	Valstybinė vaistų kontrolės tarnyba	1091049
PL	Rejestru Produktów Leczniczych	100438093
US	FDA, National Drug Code	0173-0896